<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00221429</url>
  </required_header>
  <id_info>
    <org_study_id>R01MH063632</org_study_id>
    <secondary_id>DSIR CT-M</secondary_id>
    <nct_id>NCT00221429</nct_id>
  </id_info>
  <brief_title>Lithium Versus Divalproex for Treating Pediatric Bipolar Disorder</brief_title>
  <official_title>Pediatric Bipolar Collaborative Mood Stabilizer Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Cincinnati</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Mental Health (NIMH)</source>
  <brief_summary>
    <textblock>
      This study will compare the efficacy of lithium, divalproex, and placebo in treating the&#xD;
      acute phase of symptomatic bipolar I disorder, mixed or manic episode, in children and&#xD;
      adolescents.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Aim:&#xD;
&#xD;
      To compare the efficacy of LI, DVP, and PBO in the acute phase treatment of symptomatic&#xD;
      bipolar I disorder, mixed or manic episode, in children and adolescents. Our hypothesis is&#xD;
      that differential efficacy will be observed with the following predicted order of response:&#xD;
      DVP = LI &gt; PBO.&#xD;
&#xD;
      Secondary Aims:&#xD;
&#xD;
        1. To collect systematic safety data on the incidence of weight gain and the development of&#xD;
           insulin resistance and hyperandrogenism in bipolar adolescent females treated with LI,&#xD;
           DVP, or LI + DVP.&#xD;
&#xD;
        2. To collect data on possible predictors of acute treatment response to the two active&#xD;
           treatments.&#xD;
&#xD;
        3. To provide descriptive information on the stability of acute phase response to&#xD;
           monotherapy with either LI or DVP over 6 months of continuation phase treatment.&#xD;
&#xD;
        4. To develop safety and efficacy data about the use of stimulant medications in these&#xD;
           subject while treated with a mood stabilizer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>March 2001</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>YMRS &amp; CGI-I</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>CDRS &amp; MRS</measure>
  </secondary_outcome>
  <enrollment>154</enrollment>
  <condition>Bipolar Disorder</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lithium sodium divalproex</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 7.0 - 17 years of age&#xD;
&#xD;
          2. Bipolar I Disorder, mixed or manic episode, psychotic or non-psychotic, according to&#xD;
             DSM IV criteria&#xD;
&#xD;
          3. Score of &gt; 14 on the Y-MRS&#xD;
&#xD;
          4. Normal intelligence&#xD;
&#xD;
          5. Ability and willingness to provide assent and informed, written consent from at least&#xD;
             one parent or legal guardian&#xD;
&#xD;
          6. No current general medical illnesses requiring medication&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. A current or lifetime DSM-IV diagnosis of schizophrenia, autistic disorder,&#xD;
             schizoaffective disorder, pervasive developmental disorder, or obsessive compulsive&#xD;
             disorder 2. IQ &lt; 70 3. Patients with serious suicide risk 4. Concurrent&#xD;
             cognitive-behavior therapy that is specifically focused on the child or adolescent's&#xD;
             bipolar symptoms within 6 weeks of enrolling in this trial.&#xD;
&#xD;
             5. Any use of psychotropic agents within the preceding 2 weeks, including&#xD;
             neuroleptics, monoamine oxidase inhibitors, stimulants, antidepressants, or depot&#xD;
             neuroleptics or fluoxetine in the past month 6. Current or history in past 3 months of&#xD;
             a DSM-IV diagnosis of Substance Abuse/Dependence or use of illicit drugs or alcohol in&#xD;
             the past 3 weeks. Patients who have a positive drug screen at intake, who would&#xD;
             otherwise be eligible for the study, will be given the opportunity to repeat the drug&#xD;
             screen 3 weeks later. They will be excluded if the second drug screen is positive.&#xD;
&#xD;
             7. Pregnancy or sexually active females not using a reliable form of contraception 8.&#xD;
             Previous adequate trial of either LI or DVP defined as; 3 weeks of DVP at serum levels&#xD;
             between 75-125 OR dosage of at least 20 mg/kg; Lithium for at least 4 weeks at serum&#xD;
             levels of .8 - 1.2 or dosage of at least 30 mg/kg.&#xD;
&#xD;
             9. Allergies to LI, DVP or chlorpromazine. 10. Bipolar subjects who are currently&#xD;
             stable on mood stabilizers or atypical neuroleptics.&#xD;
&#xD;
             11. Bipolar subjects with Bipolar I disorder and ADHD who are stable on stimulants&#xD;
             with or without concurrent mood stabilizers.&#xD;
&#xD;
             12. Inpatient hospitalization within 6 months prior to screening. Partial&#xD;
             hospitalization is acceptable.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert A Kowatch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cincinnati</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Cincinnati Medical Center/Medical Sciences Building</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2002</verification_date>
  <study_first_submitted>September 14, 2005</study_first_submitted>
  <study_first_submitted_qc>September 21, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>February 22, 2006</last_update_submitted>
  <last_update_submitted_qc>February 22, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 23, 2006</last_update_posted>
  <keyword>child</keyword>
  <keyword>adolescent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valproic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

